Latest Conference Coverage

The cofounder and chief scientific officer of Xcell Biosciences discussed the limitations of the methods currently used for modeling in preclinical cell therapy research for solid tumors.

New data from imaging analyses on RG6501 were presented at the ARVO 2023 Annual Meeting.

The senior director of immunology at Arsenal Bio discussed advantages of ICTs and the company’s clinical trial in ovarian cancer.

The study found significant improvements in BCVA, in contrast to several other studies evaluating Luxturna.

The data, presented at ARVO's 2023 conference, also showed a favorable safety profile.

The vice president of business development and alliances at Prescient Therapeutics discussed the mechanism of the OmniCAR technology.

The chief scientific officer of Aurion Biotech discussed the properties of the cell therapy for corneal dystrophies, which was recently approved in Japan.

The new data builds upon positive long-term follow-up data from clinical trials.

The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed early data from a phase 1 trial of the PBMC-derived therapy.

The safety profile of lenadogene nolparvovec at 5-years post treatment was similar to 2-year data.

The associate director of research at Lyell Immunopharma discussed the company’s programs and newest technologies aimed at solid tumors.

The instructor at Stanford Institutes of Medicine discussed the key takeaways of her research into the factors that affect CAR-T expansion.

No serious TEAEs have been related to ATSN-101 with data up to 6 months after treatment.

The chief scientific officer of Aurion Biotech discussed the investigational cell therapy AURN001.

STZ eyetrial’s treatment rAAV8.hPDE6A was otherwise deemed well-tolerated.

The commercially available gene therapy, developed by Spark Therapeutics, was evaluated in multiple studies presented at ARVO’s 2023 conference.

The new positive data on the AAV based gene therapy builds upon real-world data presented at ARVO’s conference in 2022.

The research scientist at Moffitt Cancer Center discussed the results of the preclinical study she presented at the 2023 AACR annual meeting and avenues for further research.

The professor of breast cancer research at Indiana University discussed new research with the TONSL gene from Indiana University.

Overall, 6 patients were treated in a feasibility study for a disease control rate of 33.3%.

The research scientist at Moffitt Cancer Center shared the rationale behind the preclinical study she presented at the 2023 AACR annual meeting.

The investigators created the largest known CAR-T atlas, with more than 800,000 cells in total, providing a new exploration into the phenotyping of T-cells.

Vax-CAR-T cells significantly suppressed tumor growth in mouse models in both smaller and larger tumors.

The assistant professor of stem cell transplantation at MD Anderson Cancer Center discussed updated data on ALLO-316 in patients with ccRCC.

Recent data supported the TCR therapy’s pending BLA submission.

Among patients treated at the higher dose level in the investigator-initiated clinical trial, the objective response rate was 50%.

Next steps may include assessing AFM13 in combination with natural killer cells.